[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631266":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":19,"locations":19,"responsibleParty":20,"collaborators":19,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":19,"eligibilityCriteria":30,"healthyVolunteers":26,"sex":31,"minAge":32,"maxAge":33,"enrollmentInfo":34,"targetDuration":19,"studyType":37,"phases":38,"briefSummary":40,"conditions":41,"keywords":43,"overallStatus":46,"whyStopped":19,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":19},{"fullName":5,"class":6},"Tianjin Medical University General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"A single-arm TILs treatment","EXPERIMENTAL","Experimental: Surgically collect fresh tumor tissue or malignant pleural effusion to isolate immune cells, and prepare TILs Infusion. Trial product: TILs Injection. Administration route: Intravenous Infusion",[13],"Drug: TILs injection",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","TILs injection",[9],null,{"type":21,"investigatorFullName":22,"investigatorTitle":23,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Zuoqing Song","Chief Physician","100631266","early-phase-1-tils-therapy-for-multiple-primary-early-stage-nsclc-100631266",false,"NCT07498439","TILs Therapy for Multiple Primary Early-Stage NSCLC","Safety Study of Tumor-Infiltrating Lymphocytes (TILs) Therapy for Multifocal Early-Stage Non-Small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n1. Age 18-75 years, male or female;\n2. Imaging findings showing multiple pulmonary nodules persisting after one year of follow-up, clinically diagnosed as multiple lung cancers by two associate senior or higher-level radiologists, two associate senior or higher-level thoracic surgeons, and one associate senior or higher-level oncologist, with patients refusing continued observation;\n3. Patients with a history of surgical resection and pathological diagnosis of NSCLC, who subsequently show disease progression on imaging (progression of primary lesion or new nodules) during follow-up or after targeted therapy, diagnosed as lung cancer by a multidisciplinary expert team, and who refuse surgery or other treatments;\n4. Ability to obtain a tumor sample of approximately 1-1.5 cm³ via surgery, biopsy, or bronchoscopy for preparation of autologous tumor-infiltrating lymphocytes;\n5. ECOG performance status score of 0-2;\n6. HGB ≥70 g\u002FL, transfusion-eligible;\n7. No severe hepatic, renal, cardiac, or pulmonary dysfunction, meeting the following criteria:\n\n   Creatinine ≤ 1.5 × ULN; Oxygen saturation \\> 90%; Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN;\n8. Estimated survival \\> 5 years with complete clinical documentation.\n\nExclusion Criteria:\n\n1. Patients with pathological diagnosis of small cell lung cancer components;\n2. Suspicious lesions appearing and follow-up duration less than six months, or remission after anti-inflammatory treatment;\n3. Previous history of allogeneic organ transplantation or cytoreductive therapy including lymph node clearance;\n4. Patients currently undergoing steroid therapy;\n5. Concurrent severe or persistent infections unresponsive to effective control;\n6. Concurrent severe autoimmune disease or congenital immunodeficiency;\n7. History of severe allergic reactions to biological products (including antibiotics);\n8. Active hepatitis (quantitative hepatitis B virus DNA \\[HBV-DNA\\] above the lower limit of detection for the assay method, or positive hepatitis C antibodies \\[HCV-Ab\\] with HCV-RNA above the assay method's lower limit of detection);\n9. HIV infection or syphilis infection;\n10. Female patients who are pregnant, breastfeeding, or planning pregnancy within 12 months;\n11. Conditions deemed by the investigator to potentially increase subject risk or interfere with trial results.","ALL","18 Years","75 Years",{"count":35,"type":36},50,"ESTIMATED","INTERVENTIONAL",[39],"EARLY_PHASE1","This is a single-arm study aimed at evaluating the safety of TILs therapy for multiple primary early-stage NSCLC",[42],"Primary Early-stage Non-small Cell Lung Cancer",[44,45],"TILs","NSCLC","NOT_YET_RECRUITING","2026-03-25",{"date":49,"type":50},"2026-03-27","ACTUAL",{"date":52,"type":36},"2026-03-31",{"date":54,"type":36},"2030-03-31",{"name":5,"class":6}]